This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue Reading
MOSAIC is a five-year global project to accelerate introduction and scale-up of new biomedical prevention products and expedite their availability, acceptance, uptake, and impact in PEPFAR programs to help individuals, especially women, prevent HIV and other infectious diseases.
This workshop will explore what is needed to ensure that introductory research and programs are strategically designed, user-centered, and appropriately resourced to support successful rollout of CAB PrEP.
Continue ReadingSub-Saharan Africa is home to 25.3 million (67%) of the global total of 37.7 million people living with HIV infection (UNAIDS 2021). To control the epidemic in Africa, it is essential that solutions for Africa be generated and implemented in Africa.
Continue ReadingAs we move toward a multi-product HIV prevention market, adolescent girls and young women must be empowered to choose an HIV prevention product that meets their needs.
Continue ReadingWith the dapivirine vaginal ring and injectable cabotegravir poised to join oral pre-exposure prophylaxis (PrEP) as safe, effective HIV prevention products, people seeking an HIV prevention method that works for them will soon have real choices.
Continue ReadingFor Zimbabwe and other countries in eastern and southern Africa, the emergence of new forms of PrEP presents a remarkable opportunity to offer potential users a range of choices to better meet their HIV prevention needs.
Continue ReadingWhen countries introduce novel HIV prevention products, such as the PrEP ring and injectable CAB PrEP, how will women decide which product to use, and what will influence those decisions?
Continue ReadingToday, we observe International Women’s Day, a day to celebrate the many achievements of women around the globe.
Continue ReadingIn the MOSAIC project, the end user—that is, the people who need and/or want to use biomedical HIV prevention (PrEP) products—is at the center of all that we do.
Continue ReadingIn this webinar, we explore ongoing and completed research on CAB PrEP, learn about the recently released FDA guidance, and hear from a panel of implementers and policymakers on what is needed to advance introduction of this new HIV prevention product.
Continue ReadingWhen I was a medical student in the early 1990s, the only drug we had to treat HIV was azidothymidine (AZT). I remember the excitement when combination therapy was developed; we all embraced a new acronym: HAART – highly active antiretroviral therapy.
Continue Reading